Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures

Neurology

Volumn 49, Issue 3, 1997, Pages 746-752

  Beydoun, A ^a   Fischer, J ^b   Labar, D R ^c   Harden, C ^c   Cantrell, D ^d   Uthman, B M ^e   Sackellares, J C ^e   Abou Khalil, B ^f   Ramsay, R E ^g   Hayes, A ^h   Greiner, M ^h   Garofalo, Elizabeth ^h   Pierce, M ^h  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF MIAMI   (United States)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN;

ADOLESCENT; ADULT; ARTICLE; ATAXIA; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; ELECTROENCEPHALOGRAPHY; FATIGUE; FEMALE; GRAND MAL SEIZURE; GRANULOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VERTIGO;

EID: 0030776298     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.3.746     Document Type: Article

References (11)

1. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335:1114-1117.
2. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-2298.
3. Bergey GK, Morris HH, Rosenfeld W, et al. Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. Neurology 1997; 49:739-745.
4. Pledger GW, Schmidt D. Evaluation of antiepileptic drug efficacy: a review of clinical trial design. Drugs 1994;48:498-509.
5. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology 1993;43:688-692.
6. Leber PD. Hazards of inference: the active control investigation. Epilepsia 1989;30(suppl 1):S57-S63.
7. Cereghino JJ. Clinical trial design for antiepileptic drugs. Ann Neurol 1992;32:393-394.
8. Duncan JS, Shorvon SD, Trimble MR. Discontinuation of phenytoin, carbamazepine, and valproate in patients with active epilepsy. Epilepsia 1990;31:324-333.
9. The US Gabapentin Study Group. The long-term safety and efficacy of gabapentin (Neurontin) as add-on theraphy in drug-resistant partial epilepsy. Epilepsy Res 1994;18:67-73.
10. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, ed. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine Services, 1993: 41-46.
11. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10:276-281.